Brokerages Set Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Target Price at $14.33

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) has received an average recommendation of “Buy” from the seven brokerages that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, four have issued a buy rating and two have issued a strong buy rating on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $14.3333.

EPRX has been the topic of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating and set a $12.00 price target on shares of Eupraxia Pharmaceuticals in a research note on Friday, January 9th. Wall Street Zen raised Eupraxia Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, December 13th. Lifesci Capital upgraded Eupraxia Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, December 11th. Cantor Fitzgerald increased their price objective on Eupraxia Pharmaceuticals from $11.00 to $19.00 and gave the stock an “overweight” rating in a research report on Thursday, January 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a report on Thursday, January 22nd.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in EPRX. Marshall Wace LLP purchased a new position in Eupraxia Pharmaceuticals in the fourth quarter valued at about $1,194,000. Ingalls & Snyder LLC grew its holdings in shares of Eupraxia Pharmaceuticals by 31.0% in the 4th quarter. Ingalls & Snyder LLC now owns 77,400 shares of the company’s stock worth $584,000 after acquiring an additional 18,300 shares during the period. Jane Street Group LLC purchased a new position in Eupraxia Pharmaceuticals in the 4th quarter valued at approximately $223,000. Cibc World Market Inc. raised its holdings in Eupraxia Pharmaceuticals by 287.0% during the fourth quarter. Cibc World Market Inc. now owns 58,050 shares of the company’s stock worth $437,000 after purchasing an additional 43,050 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its position in Eupraxia Pharmaceuticals by 44.8% during the fourth quarter. Goldman Sachs Group Inc. now owns 58,058 shares of the company’s stock worth $438,000 after purchasing an additional 17,958 shares in the last quarter.

Eupraxia Pharmaceuticals Price Performance

NASDAQ:EPRX opened at $8.42 on Monday. The firm has a market cap of $302.78 million, a price-to-earnings ratio of -9.68 and a beta of 1.20. The firm’s fifty day moving average price is $7.81 and its 200 day moving average price is $6.44. Eupraxia Pharmaceuticals has a 1-year low of $2.68 and a 1-year high of $9.32.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.